The emerging relevance of the gut microbiome in cardiometabolic health.
The emerging relevance of the gut microbiome in cardiometabolic health.
复制标题
肠道微生物组在心脏代谢健康中的作用正在显现。
DOI:
10.1007/s12170-013-0357-2
复制
发表时间:
2013-12-01
影响因子:
1.9
通讯作者:
Ordovas JM
中科院分区:
文献类型:
--
作者:
Obin M;Parnell LD;Ordovas JM
Humans are super-organisms or “holobionts”[1] composed of 10% human cells and 90% microbial cells [2], and the health and survival of both have co-evolved to become inextricably intertwined. Thus, vital host metabolic pathways and physiological responses, including lipid and bile acid metabolism and inflammatory response, are regulated by “cross-talk” between the host and the gut microbial community, or “microbiota”[3]. Perhaps not surprisingly, the gut microbiota is increasingly recognized as an agent of sickness, with dysregulation in the gut microbiota, or “dysbiosis,” emerging as both a feature and potential cause of cardiometabolic disease. The pace and scope of discovery in this arena reflects our increasing ability to incorporate powerful ‘omics’ technologies—in particular genomics, metagenomics, and metabolomics—into preclinical and clinical studies.It is well-established that cardiovascular complications are the leading causes of morbidity and mortality in individuals with obesity, insulin resistance, and type 2 diabetes mellitus (T2DM). This association reflects in large part the deleterious impacts of systemic inflammation, lipotoxicity, and oxidative stress on endothelial function that accompany these conditions [4, 5]. Studies over the last decade have demonstrated that gut microbial dysbiosis can, by altering the balance between circulating and stored lipids, and by promoting systemic inflammation (metabolic endotoxemia), promote obesity,